Addex Therapeutics shareholders approved all proposals of the Board of Directors at the company's 2026 Annual General Meeting, with votes representing 29.35% of outstanding capital. The approved items included the 2025 annual report, consolidated and annual financial statements, appropriation of results, and the compensation report in a consultative vote. Shareholders also re-elected all board members, including Dr. Vincent Lawton as chairman, and approved amendments to the Articles of Association to increase the capital band and conditional share capital. BDO SA was re-elected as auditor and Robert P. Briner as independent voting rights representative until the 2027 AGM.
Addex Therapeutics LtdShareholders approved routine governance items including financial statements, board re-election, and capital band increase, which are standard procedural matters with no clear positive or negative impact on the company's operations or value.